在接受乐伐替尼和阿替利珠单抗联合贝伐单抗治疗肝细胞癌后行肝切除的患者中，瘤周区域肿瘤浸润淋巴细胞计数的差异
Differences in Tumor-Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma.
作者信息
Toshida Katsuya, Itoh Shinji, Tanaka Yasushi, Toshima Takeo, Yoshiya Shohei, Izumi Takuma, Iseda Norifumi, Tsutsui Yuriko, Nakayama Yuki, Ishikawa Takuma, Ninomiya Mizuki, Iwasaki Takeshi, Oda Yoshinao, Yoshizumi Tomoharu
机构信息
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
出版信息
Cancer Med. 2025 Apr;14(8):e70445. doi: 10.1002/cam4.70445.
AIM
With advances in systemic therapy, the number of patients with hepatocellular carcinoma (HCC) who can undergo hepatic resection has increased in recent years, but there are no reports evaluating the immune status in the peritumoral area.
METHODS
We enrolled 14 patients who underwent hepatic resection after lenvatinib (LEN, n = 7) or atezolizumab plus bevacizumab (ATZ/BEV, n = 5) therapy. Tumor-infiltrating lymphocytes (TILs), including CD3+ and CD8+ TILs, in the peritumoral area were evaluated by hematoxylin and eosin staining and immunohistochemistry.
RESULTS
The median TIL counts after LEN and ATZ/BEV therapy were 32 and 92 cells/0.237 mm, respectively (p = 0.0044). The median CD3+ TIL counts after LEN and ATZ/BEV therapy were 26 and 71 cells/0.237 mm, respectively (p = 0.0057). The median CD8+ TIL counts after LEN and ATZ/BEV therapy were 14 and 42 cells/0.237 mm, respectively (p = 0.0044).
CONCLUSION
TIL counts, including those of CD3+ and CD8+ TILs, in the peritumoral area were significantly higher after ATZ/BEV than after LEN therapy.
目的
随着全身治疗的进展，近年来可接受肝切除的肝细胞癌（HCC）患者数量有所增加，但尚无评估肿瘤周围区域免疫状态的报道。
方法
我们纳入了14例在接受乐伐替尼（LEN，n = 7）或阿替利珠单抗联合贝伐单抗（ATZ/BEV，n = 5）治疗后接受肝切除的患者。通过苏木精-伊红染色和免疫组织化学评估肿瘤周围区域的肿瘤浸润淋巴细胞（TILs），包括CD3 +和CD8 + TILs。
结果
LEN和ATZ/BEV治疗后的TIL计数中位数分别为32和92个细胞/0.237平方毫米（p = 0.0044）。LEN和ATZ/BEV治疗后的CD3 + TIL计数中位数分别为26和71个细胞/0.237平方毫米（p = 0.0057）。LEN和ATZ/BEV治疗后的CD8 + TIL计数中位数分别为14和42个细胞/0.237平方毫米（p = 0.0044）。
结论
ATZ/BEV治疗后肿瘤周围区域的TIL计数，包括CD3 +和CD8 + TILs，显著高于LEN治疗后。
Zotero 插件